acumapimod

Acumapimod (BCT197) is an oral small molecule inhibitor of p38 mitogen-activated protein kinase (MAP kinase), developed as a first-line therapy for severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Its mechanism involves inhibiting the p38α isoform of MAP kinase, which plays a key role in inflammatory signaling pathways. By blocking this pathway, acumapimod reduces the production of pro-inflammatory cytokines such as TNFα and may improve lung function during acute COPD exacerbations. The drug has completed Phase 2 clinical development for AECOPD and was also investigated for acute kidney injury in patients undergoing cardiac surgery, though that program was discontinued. Acumapimod is administered orally and is metabolized primarily by CYP3A4; it is also a P-glycoprotein substrate[1][4][5][7].

Other names

acumapimod3-(5-amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide836683-15-9